http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11389432-B2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0fcbc9ca53bc68f405f71764197469b5 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-573 |
filingDate | 2019-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2022-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0c5cc2230d913de91183234b346ed15 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee3a1a5d470303d8d5a5ea258c9311f5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95b72331802e92ae6080672f52bf86c3 |
publicationDate | 2022-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-11389432-B2 |
titleOfInvention | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
abstract | Novel methods for treating cancer include: administering a glucocorticoid receptor modulator (GRM) to a patient, and determining whether or not the expression level of a gene is decreased in comparison with baseline levels of the gene measured in the patient prior to the GRM administration, thereby identifying a patient as being likely to benefit from cancer chemotherapy in conjunction with GRM administration where the expression level of a gene following GRM administration is decreased in comparison with corresponding gene baseline levels; and administering to said identified patient a combination of a GRM and cancer chemotherapy, whereby the cancer is treated in the patient. n The GRM may be selected from relacorilant, CORT125281, CORT122928, and CORT113176. The cancer chemotherapy agent may be a taxane. The gene expression level measured may be selected from 50 identified genes, and may be selected from COX2, DUSP1, GSK3b, MCL-1, PIK3CG, RGS-2, SGK1, and STAT3. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021369690-A1 |
priorityDate | 2018-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2292.